Shaun A. Kirkpatrick

RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona.

Sertoli Technologies, Inc. provides medical services. It develops products to treat insulin-dependent diabetes and hemophilia. The company technology enables treatment of life-threatening diseases caused by a patient's impaired ability to produce a protein, such as insulin in diabetes or factor XIII in hemophilia. Sertoli Technologies was founded in 1996 and is headquartered in Tucson, AZ.

DisperSol Technologies LLC offers plastics processing technology to pharmaceutical manufacturing companies. It offers KinetiSol, a pharmaceutical processing technology that provides solutions to oral drug delivery problems and for amorphous solid dispersion systems; and ArmoRx Platform, a processing technology that enables use of certain compendial pharmaceutical polymers to produce oral dosage forms that are inherently abuse deterrent. The company was founded by Gershon Yaniv in 2007 and is headquartered in Georgetown, TX.

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Imagine Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops small molecules that enable the delivery of cancer therapeutics to meta-static and primary brain tumors. The company is headquartered in San Diego, CA.

Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023.

Flinn Foundation engages as a philanthropic grantmaking organization. It helps in the advancement of the state's bioscience sector and provides education to high-achieving students at an Arizona public university. The company was founded by Robert S. Finn and Irene Flinn in 1965 and is headquartered in Phoenix, AZ.